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Background: Tumour relapse is recognized to be the prime fatal burden in patients affected by head and neck
squamous cell carcinoma (HNSCC), but no discrete molecular trait has yet been identified to make reliable early
predictions of tumour recurrence. Expression of cell surface proteoglycans (PGs) is frequently altered in carcinomas
and several of them are gradually emerging as key prognostic factors.
Methods: A PG expression analysis at both mRNA and protein level, was pursued on primary lesions derived from
173 HNSCC patients from whom full clinical history and 2 years post-surgical follow-up was accessible. Gene and
protein expression data were correlated with clinical traits and previously proposed tumour relapse markers to stratify
high-risk patient subgroups.
Results: HNSCC lesions were indeed found to exhibit a widely aberrant PG expression pattern characterized by a
variable expression of all PGs and a characteristic de novo transcription/translation of GPC2, GPC5 and NG2/
CSPG4 respectively in 36%, 72% and 71% on 119 cases. Importantly, expression of NG2/CSPG4, on neoplastic cells
and in the intralesional stroma (Hazard Ratio [HR], 6.76, p = 0.017) was strongly associated with loco-regional
relapse, whereas stromal enrichment of SDC2 (HR, 7.652, p = 0.007) was independently tied to lymphnodal infiltration
and disease-related death. Conversely, down-regulated SDC1 transcript (HR, 0.232, p = 0.013) uniquely correlated with
formation of distant metastases. Altered expression of PGs significantly correlated with the above disease outcomes
when either considered alone or in association with well-established predictors of poor prognosis (i.e. T classification,
previous occurrence of precancerous lesions and lymphnodal metastasis). Combined alteration of all three PGs was
found to be a reliable predictor of shorter survival.
Conclusions: An unprecedented PG-based prognostic portrait is unveiled that incisively diversifies disease course in
HNSCC patients beyond the currently known clinical and molecular biomarkers.
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Head and neck squamous cell carcinomas (HNSCC)
have an estimated frequency of 38,160 new cases in the
US (updated to August, 2014) [1] and an estimated oc-
currence of more than 442,000 new cases worldwide ac-
cording to GLOBOCAN 2012 [2,3], thereby representing
the primary lethal cancer entity in patients with head
and neck tumours. Loco-regional relapsing is the most
severe clinical problem encountered in these tumours,
while the pre-operative presence of lymphnodal infiltra-
tion is a recognized prognostic factor [4,5]. Especially in
patients presenting smaller primary lesions, occult sec-
ondary lesions in lymphnodes significantly complicate
the clinical management of these individuals [6-13]. The
currently adopted methods to predict disease recurrence,
such as staging and grading, are too arbitrary and do not
allow for a sufficiently accurate clinical stratification of
the patients [14,15]. This deficit calls upon the need to
identify distinct molecular markers that more reliably
would predict disease progression, recurrence and me-
tastasis formation, and many such have been proposed
over the last decade (Table 1). Thus far, however, only
three such markers have been considered as meaningful,
i.e. HPV infection, TP53 mutation status and overex-
pression of EGFR [16-20], but their full independence
from clinical parameters is still dubious.
One class of molecules with the potential of acting as
clinically relevant factors in HNSCC, especially for oral
cavity and oropharynx cancer, is that comprising cell
surface-associated proteoglycans (PGs). In fact, changes in
their relative expression are progressively being associated
with neoplastic transformation, propagation of local
tumour masses, and formation of distant metastases. This
not only in HNSCC, but also in numerous epithelial and
non-epithelial tumour types. Both PGs produced by the
HNSCC cells themselves and PGs associated with the
intra-lesional tumour stroma may play critical roles in the
control of HNSCC growth, dissemination and therapeutic
refraction, and may therefore be contemplated as putative
biomarkers as well as therapeutic targets. There are cur-
rently 15 cell surface PGs known in the human genome
with the most representative ones belonging to either the
transmembrane syndecan group, i.e. syndecan-1-4 (SDC1-
SDC4) [21-25], or the GPI-anchored glypican group, i.e.
glypican-1-6 (GPC1-GPC6) [23,26-28]. The unique struc-
tural traits of cell surface PGs enable them to modulate
directly and/or indirectly several facets of the tumour cell
phenotype and behavior, including growth kinetics, inva-
siveness and metastatic ability.
Previously documented, representative examples of the
implication of diverse PGs expressions for disease out-
come are afforded by the recently consolidated tumour-
suppressing effect of GPC5 in lung carcinomas arising in
“never smokers” [29-31], as well as by the well-establishedprognostic/predictive up-regulation of GPC1 in pancreatic
cancer [32,33]. As a corollary, GPC3 is a recognized
prognostic/predictive factor and therapeutic target in
hepatocellular carcinoma [34-37]. SDC1, the only PG for
which there is some documentation in oral squamous cell
carcinoma, seems to be associated with the differentiation
status of the tumour cells [38-40]. Clinical correlation of
SDC1 expression with disease status specifically refers to
its modulation in epithelial neoplastic cells [41-47] and
tumour stroma [48], while the PG has been proposed to
influence migration and invasion of oral squamous cell
carcinoma cells in vitro by interacting with the β1 integrin
subunit and the laminin β1 chain [48].
NG2/CSPG4 has been proposed to impact on tumour-
igenesis and evidence has been accrued suggesting that
NG2/CSPG4 alone is able to confer metastatic potential
to cancer cells by serving as a multivalent mediator of
the cancer cell-host microenvironment interactions and
by enhancing drug resistance and protecting cells from
stress-induced programmed cell death [49,50]. In an
increasing number of tumours, prognostic implications
of NG2/CSPG4 are being unveiled and these discoveries
accentuate the potential of the PG as a therapeutic target.
Recently, a direct link between methylation and CSPG4
expression in HNSCC HPV-negative/stage IVa subgroup
were proved, where high protein expression and low pro-
moter methylation were significantly associated with an
adverse progression-free and overall survival [51].
Based upon previously accrued information about the
role of PGs in cancer and the currently available experi-
mental evidences along this line, we have addressed the
possibility that the pattern of expression of individual
PGs, or groups of PGs, may act as either pro- or anti-
tumourigenic and thereby be predictive, or indicative,




Patients from whom surgical specimens were evaluated
were treated surgically at the S. Orsola-Malpighi Hospital,
at the Bellaria University Hospital in Bologna and at
the Maxillo-Facial Surgery Division, Department of
Head and Neck Surgery of the University of Parma. A
total of 173 surgical specimens of primary oral cavity
HNSCC were collected after informed consent ob-
tained from each enrolled patients, all of them in
adulthood (Additional file 1: Table S1; Additional file 2:
Figure S1). Patients were referred to adjuvant radiation
therapeutic treatment according to the guidelines defined
by the National Comprehensive Cancer Network (NCCN)
Clinical Practice (Version 2.2014; www.nccn.org). Clinical
data were collected within the 2 years-post surgical
follow-up every 6 months (Additional file 3; Additional file
Table 1 Previously proposed prognostic biomarkers in HNSCC1
Biomarker2 Clinical outcome Method of
detection
N. of cases/%/type of
modulation
Annotation
ADAM17 Lymph nodal metastasis/Loco-regional
relapse
IHC/WB 50/46/Up None
CD44 OS/DFS IHC 138/59/Down None
E-cadherin Recurrence/OS IHC 50/20/Up 112/59/Down None






FHIT OS/DFS IHC 53/61/Down None
GLUT1 OS IHC 40/26/up Poor radiation response
HIF1A OS/DFS IHC 85/63/Down None
Keratin-18 OS IHC 308/54/Up None
Keratin-8 OS IHC 308/54/Up None
Laminin γ2 DSS DNA Microarray 119/NS/Up None
MCM5 OS IHC 97/61/Up None
MET OS IHC 69/82/Up None
Moesin OS IHC 103/NS/Up Cytoplasmic expression pattern
Mucin-1 OS/DFS/Lymphnodal metastasis IHC 206/39/Up Within 5-years follow-up
Mucin-4 OS/DFS/Lymphnodal metastasis/Loco-
regional relapse
IHC 150/41/Up Within 5-years follow-up
p21 OS IHC 192/71/Down None
p27 DFS IHC 192/80/Down Only in patients with lymphnodal
infiltration
p57 OS IHC 67/87/Down None
p63 OS IHC 62/NS/Up None
P-cadherin Disease recurrence/Loco-regional relapse/
OS
IHC 50/20/Down 67/45/Down 108/
16/Down
None
Podoplanin DSS IHC 35/56/Up None
Rb DFS IHC 220/49/Down Only in p53+/pRb− patients
RUNX3 OS IHC/WB 108/46/Down None
S100A2 DFS/Cervical metastasis RT-PCR + seq/IHC 135/26/Down 52/NS/Down Nuclear expression pattern
SPARC OS/DFI DNA Microarray/
IHC
62/NS/Up None
STAT1 OS IHC 89/NS/Up None
Survivin 3α OS RT-PCR 97/NS/Up Only in lymphnodes
TERT OS IHC 62/NS/Up None
Ezrin OS IHC 47/85/Up Cytoplasmic expression pattern
1Specifically referred to oral and oropharyngeal squamous cell carcinoma;
2Alterations of TP53, CCND1 and FGFR4 genes are not included;
Abbreviations: OS, Overall Survival; DFS, Disease Free-Survival; DSS, Disease Specific-Survival; DFI, Disease Free-Interval; IHC, Immunohistochemistry; WB, Western
Blotting; nPCR, nested Polymerase Chain Reaction; NS, Not Specified.
Farnedi et al. BMC Cancer  (2015) 15:352 Page 3 of 192: Figure S1). The present study has been approved by the
local ethics committees (Comitato Etico Provinciale di
Parma –Parma University Hospital e Comitato Etico
Provinciale di Bologna-Bologna University Hospital)
and was conducted in compliance with the Helsinki
Declaration’s Ethical Principles for Medical Research
Involving Human Subjects.RNA extraction and qPCR
Total RNA from healthy specimens and 119 neoplastic
specimens were extracted using Trizol® according to the
manufacturer’s instructions and in combination with
Qiagen RNAeasy Mini Kit (Qiagen). Total RNA (1 μg)
was reverse-transcribed with the QuantiTect® Reverse
Transcription Kit (Qiagen). Each TaqMan Low Density
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PGs. The assays were chosen among the TaqMan Gene
Expression Assay library (Additional file 3) and the cards
were run on ABI PRISM 7900 HT Fast Real-Time PCR
System (Applied Biosystems Inc., Foster City, CA, USA).
Changes in gene expression levels were calculated using
the “relative quantification method”. Relative gene expres-
sion fold-change were expressed as Log_2(2^-ΔΔCt) and to
visualize the obtained expression profiles we used heatmap
graphing by EPCLUST – Expression Profile data CLUSTer-
ing and analysis software (www.bioinf.ebc.ee/EP/EP/
EPCLUST/) [52]. The data presented herein have been de-
posited in NCBI’s Gene Expression Omnibus [53] and are
accessible through GEO Series accession number
GSE33788 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE33788) (Additional file 3).
Tissue microarray (TMA) construction
Tissue specimens form a total of 163 patients, which
were independently assured to contain representative
areas of the neoplastic lesions, were selected for TMA
construction according to a previously described proced-
ure [54,55]. Cases were considered representative when at
least 50% of the section was composed of neoplastic cells.
For each case, the core portion of the section with the
highest percentage of tumour cells was used for analysis
(Additional file 3).
Immunohistochemistry
Details on the antibodies used, characteristics of con-
trol tissues and experimental procedures are reported
in Additional file 3. Relative antigen expression was
assessed semi-quantitatively according to the arbitrary
scoring: “-” = no positive cells were detected, “+” <10%
of cells were positive, ≥10% “++” <50% of cells were
positive, ≥50% “+++” <90% of cells were positive, and
“++++” ≥90% of cells were positive.
Statistical and bioinformatic analyses
Demographic data, presence of recognized risk factors for
development of HNSCC, clinical diagnostic parameters,
gene expression and protein distribution patterns for
the PGs GPC1-6, SDC1-4 and NG2/CSPG4 were com-
paratively evaluated for their potential correlation with
the following disease outcomes: loco-regional recurrence,
lymphnodal metastasis, distant metastasis, disease-related
deaths and probability of incurring into one or more of
these clinical outcomes. Estimation of influence of each
variable considered for the above disease outcomes was
analyzed independently with both the Log-rank and
Wilcoxon’s rank test. Survival rate was estimated using
the Kaplan-Meier method from the time of surgery to the
end of the follow-up. Cox’s multivariate proportional haz-
ards regression method was used to extract a parsimoniousset of independent variables. All analyses were performed
using the Statgraphics Centurion XVI software (StatPoint
Technologies, Inc, Virginia, USA). P values <0.05 were con-
sidered to be significant (Additional file 3).
Results
Transcriptional profiles of PGs in primary oral cavity
HNSCC lesions
Analyses of the relative mRNA expression levels of the
eleven prevalent cell surface-associated PGs conducted
on a total of 119 primary oral cavity HNSCC lesions re-
vealed that 3 of the PGs, including NG2/CSPG4, GPC2
and GPC5, were de novo expressed in neoplastic cells,
i.e. were not detectable in the healthy control tissues, but
were detectable in cancer cells. These were transcribed
in 71% (NG2/CSPG4), 36% (GPC2) and 72% (GPC5) of
the lesions, respectively. The remaining 8 PGs, for
which transcripts were expressed at a frequency of 84%
(GPC1), 86% (GPC3), 88% (GPC4), 70% (GPC6), 100%
(SDC1), 94% (SDC2), 93% (SDC3) and 95% (SDC4) of
the tumour cases, respectively, were found to be differ-
ently modulated. Thus, SDC2, SDC3 and SDC4 were
up-regulated in 79-84% of the patients, whereas GPC4
was enhanced in 11% and GPC3 in 57% of the speci-
mens. However, GPCs were more frequently down-
regulated (GPC3, 22%; GPC4, 21%; GPC1, 24%; and
GPC6 30%) than SDCs (SDC1, 8%; SDC2, 8%; SDC3, 11%;
and SDC4, 7%; Figure 1a; Additional file 4: Table S2).
We next compared the PG expression patterns exhib-
ited by discrete groups of patients differentiated by
tumour staging, i.e. T1-T2/N- versus T1-T2/N+ and T3-
T4/N- versus T3-T4/N+. GPC2 was expressed in a mere
19% of the T3-T4/N- classified lesions, whereas it was a
two-fold more frequently transcribed in patients belong-
ing to the other three classes (T1-T2/N-, 36%, T1-T2/N
+, 40% and T3-T4/N+, 42%). GPC5 and NG2/CSPG4
were detectable in samples of a large proportion of pa-
tients, ranging from 62% in T3-T4/N- to 80% in T1-T2/
N-, but their relative expression levels did not discrimin-
ate between the above patient subsets (Figure 1b). GPC1
was similarly differently expressed in the distinct groups
of patients with a 1.5-fold higher frequency in the T3-
T4/N- patients compared to the other patient subsets.
GPC4 was down-regulated in about 27% of the T1-T2/
N- and T3-T4/N+ subgroups, and <13% in the T1-T2/N
+ and T3-T4/N- patient subgroups (Figure 1b). Synde-
cans were generally up-regulated in most of the lesions
(Figure 1b), with SDC4 showing enhanced expression in
100% of T1-T2/N+ patients.
Immunolocalization of PGs in oral cavity HNSCC lesions
Intralesional distribution of PGs was further examined in
oral cavity HNSCC lesions and control healthy tissue
using empirically validated, pre-selected antibodies against
Figure 1 Cell surface-associated PGs are differentially expressed in primary lesions of oral cavity HNSCC patients. (a) Heat map and hierarchical
clustering of the relative expression levels (columns) of the 8 most modulated cell surface-associated PGs in primary lesions of 119 oral cavity
HNSCC patients (rows): red, up-regulation; green, down-regulation, black: no change in comparison to the healthy epithelial tissue. Distance between
clusters was calculated as reported in Additional file 3. (b) PG expression profiles in oral cavity HNSCC specimens derived from T1-T2-N-, T1-T2-N+, T3-
T4-N- and T3-T4-N+ graded tumours. SDC1-4, syndecans 1–4; GPC1-6, glypicans 1–6.
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Figure S2). The percentage of cases in which GPCs
could be disclosed on the epithelial neoplastic cells var-
ied from 18% (30 out of 163 cases) for GPC3 to 72%
for GPC1 (118 out of 163 cases; Table 2). Relative fre-
quency of expression was in the order: GPC1 > GPC4
(41%; 67 out of 163 cases) > GPC6 (37%; 61 out of 163cases) > GPC3. GPCs were often detected within the
cytoplasm as well as on the cell membrane, consistent
with their thoroughly described internalization and
recycling patterns. The hybrid cell membrane/cytoplasmic
distribution of these PGs was characteristically observed
for GPC1, GPC3 and GPC4, with GPC1 being most
strongly associated with these two cellular compartments
Figure 2 In situ immunolocalization of GPCs and NG2/CSPG4 in oral cavity HNSCC primary lesions. Representative patterns of GPC and NG2/
CSPG4 distribution in oral cavity HNSCC lesions. (a, b) representative views of GPC1 expression in lesions with different degrees of keratinizing
neoplastic cells. (c, d) representative images of GPC1 expression in stromal cells of pre-malignant lesions (c) and lack of expression in the stromal
cells of HNSCC tissue (d). GPC3 was detected in neoplastic cells (e), but not stromal fibroblasts (f), whereas GPC4 (g) and GPC6 (h) were primarily
found to be associated with the neoplastic cells. (i) Shows the lack of expression of GPC6 in the intralesional stroma. NG2/CSPG4 was found to
be abundantly expressed in both well- (k) and moderately-differentiated (l) oral cavity HNSCC lesions, whereas it was similarly absent from poten-
tially pre-malignant lesions (j).
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S2). GPC3 was entirely absent in healthy tissue, while
GPC4 showed a widespread distribution both on normal
epithelial cells and in the intralesional stromal compart-
ment (Additional file 5: Figure S2). GPC6 appeared to be
preferentially retained within intracellular vesicles (Figure 2),
as deduced by the appearance of GPC6-positive granules
throughout the cytoplasm of neoplastic cells. This seemedrather specific for tumour cells since it was not observed in
healthy epithelial cells (Additional file 5: Figure S2). GPC1
and GPC6 were rarely seen in the intralesional stroma of
oral cavity HNSCC lesions (13 out of 163 and 16 out of 163
of the cases, respectively), whereas GPC3 was consistently
absent from this compartment and GPC4 showed a some-
what more frequent expression in stromal cells (19%; 31
out of 163 of the cases; Table 2; Figure 2).
Figure 3 Immunodetection of SDCs in oral cavity HNSCC primary lesions. Representative view of the SDC1 expression pattern, inversely correlating with
the overall differentiation status of the tumour (a, displatyc tissue; b, c, well-differentiated; d, poorly differentiated), while being particularly abundant in the
center of neoplastic nests (p) and in the stromal compartment (e-f). SDC2 was seen strongly associated with tumour vessels (g, n, o) and was the only PG
to be widely expressed in the different degree of dysplastic tissue (h-j). SDC3 (k) and SDC4 (m) immunolocalized in the epithelial tumour cells, but not in
the stromal compartment (l, SDC3; m, SDC4).
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with a relative frequency of positive cases decreasing in
the order: SDC1 > SDC3 > SDC4 > SDC2 (Table 2). In
fact, a total of 149 cases out of 163 lesions that were
evaluated for the in situ expression of the SDC1/CD138
protein had epithelial neoplastic cells presenting the PG
on the cell surface, or in intracellular locations (Figure 3).
In contrast, a mere 57 (35%), 32 (19.6%), and 19 (12%)out of 163 examined lesions had epithelial neoplastic
cells staining positively for respectively SCD2, SDC3 and
SDC4 (Table 2). The relative number of cancer cells that
expressed these PGs in each lesion markedly differed
and a similar divergence was seen in terms of subcellular
localization of the molecules. Thus, neoplastic cells with
plasma membrane-associated SDC1 were mainly kera-
tinizing cells located at the center of the neoplastic nests
Table 2 Patterns of the in situ distribution of PGs in HNSCC lesions (% of cases)
PG Tumor cell positivity1 Overall staining intensity2 Subcellular localization3 Stromal expression
GPC1 - (27.5) - (27.6) Membrane - - (92.0)
+ (29.2) + (33.1) Cytoplasmic - + (6.7)
++ (33.1) ++ (30.1) Both (72.4) ++ (0.6)
+++ (7.4) +++ (6.7) +++ (0.6)
++++ (2.5) ++++ (2.5) ++++ -
GPC3 - (81.6) - (81.6) Membrane - - (100.0)
+ (14.1) + (14.1) Cytoplasmic - + -
++ (3.1) ++ (4.3) Both (18.4) ++ -
+++ (1.2) +++ - +++ -
++++ - ++++ - ++++ -
GPC4 - (58.9) - (59.5) Membrane - - (81.0)
+ (20.9) + (14.1) Cytoplasmic (40.5) + (5.5)
++ (19.0) ++ (25.8) Both - ++ (12.9)
+++ (1.2) +++ (0.6) +++ (0.6)
++++ - ++++ - ++++ -
GPC6 - (62.2) - (62.6) Membrane - - (90.2)
+ (30.1) + (31.9) Cytoplasmic (37.4) + (9.8)
++ (7.4) ++ (5.5) Both - ++ -
+++ - +++ - +++ -
++++ - ++++ - ++++ -
SDC1 - (8.6) - (8.6) Membrane (42.9) - (79.1)
+ (31.3) + (25.8) Cytoplasmic (37.4) + (9.2)
++ (33.7) ++ (50.3) Both (10.4) ++ (10.4)
+++ (22.1) +++ (10.4) +++ (1.2)
++++ (4.3) ++++ (4.9) ++++ -
SDC2 - (88.3) - (88.3) Membrane (1.8) - (26.4)
+ (6.7) + (8.0) Cytoplasmic (8.6) + (20.2)
++ (4.3) ++ (3.1) Both - ++ (25.8)
+++ (0.6) +++ (0.6) +++ (21.5)
++++ - ++++ - ++++ (6.1)
SDC3 - (65.0) - (65.0) Membrane - - (100.0)
+ (27.0) + (28.2) Cytoplasmic - + -
++ (6.1) ++ (6.7) Both (34.4) ++ -
+++ (1.8) +++ - +++ -
++++ - ++++ - ++++ -
SDC4 - (80.4) - (80.4) Membrane - - (100.0)
+ (16.0) + (19.6) Cytoplasmic - + -
++ (3.7) ++ - Both (17.8) ++ -
+++ - +++ - +++ -
++++ - ++++ - ++++ -
NG2/CSPG4 - (34.2) - (34.2) Membrane (62.6) - (96.7)
+ (38.8) + (36.8) Cytoplasmic - + (3.3)
++ (21.7) ++ (19.7) Both - ++ -
+++ (2.6) +++ (7.2) +++ -
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Table 2 Patterns of the in situ distribution of PGs in HNSCC lesions (% of cases) (Continued)
++++ (2.6) ++++ (2.0) ++++ -
1PG expression was assessed semi-quantitatively according to the arbitrary scoring: “-”, no positively staining cells were detected; “+”, <10% of cells were positive;
“++”, ≥10% and <50% of positive cells; “+++”, ≥50% and <90% of positive cells; “++++”, ≥90% of positive cells;
2Refers to the average staining intensity within the examined lesion, according to the arbitrary scoring: “-” = absent; “+”, faint; “++”, weak; “+++”, moderate;
“++++”, strong;
3Immunostaining was prevalently cell membrane-associated (“Membrane”) or diffuse cytoplasmatic (“Cytoplasmic”).
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rounded the neoplastic nests were positive for SDC1 in
34 out of 163 (21%) of the tumours. In 14 out of 163 of
the lesions (8.6%), SDC2 was immunolocalized within
the cytoplasm of neoplastic cells, while it appeared wide-
spread in the stromal cells of the majority of the lesions
(73.6%, 120 out of 163 of the cases; Figure 3) and was
particularly enriched in lesions containing desmoplastic
stroma. Intriguing was the fact that in 100% of the
lesions, SDC2 could be observed in the wall of both nor-
mal and intra-lesional blood vessels, suggesting that it
was associated with both endothelial and neovascular
pericytes (Figure 3). In contrast to SDC1 and SDC2,
both SDC3 and SDC4 were undetectable in the healthy
epithelium, or the tumour stroma, but could be immu-
nolocalized both subcellularly and on defined portions
of the cell surface of neoplastic cells, with a particular
concentration in focal plaque-like structures (Figure 3;
Additional file 5: Figure S2). Finally, the diversity of
SDCs expressions in oral cavity HNSCC lesions was
even more remarkable when considering the relative
distribution of these PGs in the stromal compartment.
In this case, the frequency of occurrence of the PGs was
largely reversed with respect to that seen in the cancer
cells and decreased in the order: SDC2 > SDC1 > SDC3 =
SDC4 (Table 2). Deviating from the pronounced intracel-
lular distribution of SDC3 and SDC4 was that of NG2/
CSPG4 which showed an exclusive cell membrane
localization in all samples in which the PG could be dis-
closed (63%). NG2/CSPG4 was rarely detected in the stro-
mal compartment (5 out of 163; Table 2; Figure 2), where,
if occurring, was concentrated on the membrane of basal
cells (Additional file 5: Figure S2).Altered expression of discrete PGs correlates with disease
outcome
All demographic and clinical-pathological traits of the
patients were initially compared by univariate analysis of
the cumulative PG expression data, except for patient cat-
egories comprised of less than 13 patients (independently
defined as a cut-off level of “statistical” exclusion). In these
correlation analyses we considered five primary disease
outcomes, including loco-regional tumour recurrence,
lymphnodal metastasis, distant metastases, disease-related
death and a situation in which at least one of the former
disease outcomes was manifested (Table 3).In order to test whether there is a relationship between
PGs transcript and protein expressions and clinicopatho-
logical parameters, a Chi-Square test was applied and just
three such correlation resulted statistically significant: N
classification and SDC2 stromal positivity, p = 0.002; alco-
hol consumption and SDC1 mRNA up-regulation, p =
0.021, and presence of precancerous lesion and SDC1
mRNA up-regulation, p = 0.016.
Although radiation therapy and excessive alcohol con-
sumption independently correlated with one or more of
the above clinical outcomes (Table 3), these parameters
were not considered in the multivariate logistic regression
analyses because of being potentially confounding indica-
tors. The first because almost all patients presenting
lymphnodal infiltrations had been routinely subjected to
radiation therapy, the second because, despite of its well-
recognized importance as a risk factor in HNSCC, the
admission of this habit was measured by a self-provided
questionnaire and no details were available on the accur-
acy of the information provided by the patients. A further
consideration is that self-reported excessive alcohol intake
is often denied, causing underestimation of the cohort of
patient that may fall under this “risk category”.
Advanced T classification (p = 0.007), T3-T4 grouping
(p = 0.001; Figure 4), positive NG2/CSPG4 transcript
expression (p = 0.029; Figure 4), or GPC1 positivity in
stromal cells (p = 0.007) were all conditions strongly as-
sociated with a high loco-regional tumour relapse rate
(Table 3). Stromal GPC6 expression could, however,
not be included as a parameter in the multivariate
logistic regression model due to the low number of
cases contained within this category and the borderline
statistical significance in univariate analyses (p = 0.058).
Application of the Cox proportional hazard model
revealed that T3-T4 classification of the tumour (HR,
6.36, p = 0.001) and de novo expression of NG2/CSPG4
mRNA (HR, 6.76, p = 0.017) were independent, robust
prognostic factors for local tumour recurrence (Table 4;
Figure 5). If combining T-grouping and mRNA expres-
sion of NG2/CSPG4, the probability to develop a second-
ary loco-regional lesion was further increased (p < 0.001;
Table 3; Figure 4).
Significant correlations with post-surgical lymphnodal
metastases were further disclosed between gender (p =
0.043), the presence of precancerous lesions (p = 0.003;
Figure 4), the occurrence of lymphnodal infiltration at
time of surgery (p = 0.001), stromal expression of SDC2
Table 3 Univariate analysis of PG expression in relation to known prognostic indicators




























% cases p value
Prognostic indicator
Sex Male 99 14.1 0.342 15.2 0.043 10.1 0.847 22.2 0.155 36.4 0.094
Female 74 7.0 5.4 9.5 13.5 24.3
Age ≤45 yrs 17 11.8 0.689 11.8 0.964 0.0 - 5.9 0.146 17.6 0.184
>45 yrs 156 12.2 10.9 10.9 19.9 32.7
Smoking No 66 13.6 0.689 9.1 0.466 9.1 0.718 12.1 0.109 25.8 0.253
Yes 105 11.4 12.4 10.5 21.9 34.3
Alcohol2 No 83 10.8 0.521 8.4 0.231 4.8 0.026 6.0 <0.001 21.7 0.012
Yes 88 13.6 13.6 14.8 29.5 39.8
Familial cancer history No 144 12.5 0.732 10.4 0.615 9.7 0.880 18.8 0.876 31.3 0.994
Yes 27 11.1 14.8 11.1 18.5 33.3
Precancerous lesions No 121 12.4 0.869 5.8 0.003 9.9 0.970 18.2 0.869 28.1 0.305
Yes 51 11.8 21.6 9.8 19.6 37.3
Tumor site OC 156 12.2 0.530 11.5 0.204 10.3 0.776 17.9 0.858 31.4 0.399
OP 14 7.1 0.0 7.1 21.4 21.4
OC+OP 3 33.3 33.3 0.0 33.3 66.7
T classification T1 51 3.9 0.007 7.8 0.326 2.0 0.073 5.9 0.038 17.6 0.018
T2 60 8.3 8.3 16.7 21.7 30.0
T3 17 23.5 17.6 5.9 23.5 47.1
T4 45 22.2 15.6 11.1 26.7 42.2
T1-T2 111 6.3 0.001 8.1 0.065 9.9 0.957 14.4 0.043 24.3 0.005
T3-T4 62 22.6 16.1 9.7 25.8 43.5
N classification Negative 97 9.3 0.079 5.2 0.001 5.2 0.016 9.3 <0.001 19.6 <0.001
Positive 76 15.8 18.4 15.8 30.3 46.1
Differentiation Degree Well 20 15.0 0.441 0.0 0.223 5.0 0.392 15.0 0.952 20.0 0.44
Moderate 50 16.0 12.0 14.0 18.0 36.0
Poor 78 7.7 12.8 7.7 16.7 30.8
Radiotherapy No 83 8.4 0.082 4.8 0.005 3.6 0.007 8.4 <0.001 20.5 0.002
Yes 90 15.6 16.7 15.6 27.8 41.1
PG (mRNA)3
SDC1 ↓ / = 61 11.5 0.553 6.6 0.396 4.9 0.016 11.5 0.036 21.3 0.013
↑ 58 13.8 10.3 19.0 25.9 41.4
SDC2 ↓ / = 19 5.3 0.253 5.3 0.519 5.3 0.329 10.5 0.314 15.8 0.104
↑ 100 14.0 9.0 13.0 20.0 34.0
SDC3 ↓ / = 24 8.3 0.405 8.3 0.896 4.2 0.193 20.8 0.855 25.0 0.352
↑ 95 13.7 8.4 13.7 17.9 32.6
SDC4 ↓ / = 19 5.3 0.253 5.3 0.519 5.3 0.329 15.8 0.780 26.3 0.601
↑ 100 14.0 9.0 13.0 19.0 32.0
GPC1 = 62 12.9 0.803 6.5 0.502 12.9 0.668 17.7 0.940 32.3 0.625
↓ / ↑ 57 12.3 10.5 10.5 19.3 29.8
GPC2 = 76 10.5 0.393 6.6 0.363 10.5 0.596 21.1 0.335 27.6 0.307
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Table 3 Univariate analysis of PG expression in relation to known prognostic indicators (Continued)
De novo 43 16.3 11.6 14.0 14.0 37.2
GPC3 ↓ 26 7.7 0.437 0.0 0.219 11.5 0.378 11.5 0.303 23.1 0.624
= 25 20.0 12.0 4.0 12.0 32.0
↑ 68 11.8 10.3 14.7 23.5 33.8
GPC4 = 81 11.1 0.598 7.4 0.647 13.6 0.365 21.0 0.308 33.3 0.348
↓ / ↑ 38 15.8 10.5 7.9 13.2 26.3
GPC5 = 33 12.1 0.995 9.1 0.851 6.1 0.241 15.2 0.609 30.3 0.986
De novo 86 12.8 8.1 14.0 19.8 31.4
GPC6 ↓ 36 19.4 0.351 8.3 0.994 8.3 0.495 16.7 0.838 36.1 0.824
= 24 8.3 8.3 8.3 16.7 29.2
↑ 59 10.2 8.5 15.3 20.3 28.8
NG2/CSPG4 = 34 2.9 0.029 8.8 0.914 8.8 0.487 14.7 0.401 20.6 0.077
De novo 85 16.5 8.2 12.9 20.0 35.3
PG (Protein)4
SDC1 Tumor cells Negative 14 7.1 0.447 21.4 0.312 7.1 0.769 7.1 0.269 35.7 0.947
Positive 149 13.4 10.7 9.4 19.5 31.5
Stroma Negative 129 13.2 0.962 11.6 0.812 9.3 0.998 17.1 0.294 31.0 0.429
Positive 34 11.8 11.8 8.8 23.5 35.3
SDC2 Tumor cells Negative 143 13.3 0.783 11.9 0.875 8.4 0.303 18.9 0.792 30.8 0.385
Positive 19 10.5 10.5 15.8 15.8 42.1
Stroma Negative 43 9.3 0.277 2.3 0.015 2.3 0.062 2.3 0.001 14.0 0.002
Positive 120 14.2 15.0 11.7 24.2 38.3
SDC3 Tumor cells Negative 106 13.2 0.923 12.3 0.793 8.5 0.655 17.9 0.758 30.2 0.575
Positive 56 12.5 10.7 10.7 19.6 35.7
SDC4 Tumor cells Negative 131 15.3 0.071 13.0 0.329 9.2 0.957 17.6 0.588 32.8 0.649
Positive 32 3.1 6.3 9.4 21.9 28.1
GPC1 Tumor cells Negative 44 11.4 0.653 15.9 0.340 4.4 0.214 15.6 0.602 31.8 0.825
Positive 108 13.6 10.2 10.7 18.9 32.2
Stroma Negative 149 11.4 0.007 12.1 0.884 8.4 0.319 16.8 0.012 30.9 0.104
Positive 13 30.8 7.7 15.4 38.5 46.2
GPC3 Tumor cells Negative 133 12.8 0.805 12.0 0.841 9.6 0.584 18.4 0.834 33.1 0.605
Positive 30 13.3 10.0 6.3 15.6 26.7
GPC4 Tumor cells Negative 96 13.5 0.969 10.2 0.493 9.2 0.928 17.3 0.716 33.3 0.794
Positive 66 12.1 13.0 8.7 18.8 30.3
Stroma Negative 131 13.0 0.860 11.5 0.692 9.2 0.900 18.3 0.771 32.8 0.810
Positive 31 12.9 12.9 9.7 19.4 29.0
GPC6 Tumor cells Negative 101 12.9 0.860 6.9 0.010 5.9 0.052 15.8 0.222 27.7 0.102
Positive 61 13.1 19.7 14.8 23.0 39.3
Stroma Negative 146 11.6 0.058 12.3 0.599 10.3 - 18.5 0.844 32.2 0.828
Positive 16 25.0 6.3 0.0 18.8 31.3
NG2/CSPG4 Tumor cells Negative 52 15.4 0.665 9.6 0.406 9.6 0.923 17.3 0.563 34.6 0.967
Positive 100 12.0 14.0 10.0 21.0 33.0
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SDC1 mRNA ↑ NG2/CSPG4 mRNA
de novo + SDC2
stroma
Yes 36 16.7 0.271 11.1 0.405 25 <0.001 33.3 0.002 50 <0.001
No 73 12.3 8.2 4.1 11 23.3
1This refers to the situation in which patients manifested at least one of the four adopted clinical outcomes within the follow-up period;
2Excessive alcohol consumption was based upon self-provided information;
3PG transcript expression was defined as “↓”, down-regulated; “↑”, up-regulated; “=”, not changed; and “De novo”, de novo expressed, when compared to a healthy
mucosal tissues pool that was used as sample calibrator;
4Protein expression data are reported as detectable or non-detectable by indirect immunohistochemistry;
5Univariate analyses combining the prognostic indicators that were deemed to be independent poor predictors of each of the five clinical outcomes as
accomplished through the Cox proportional hazard model;
6 N status positive or negative is according to N classification AJCC staging system;
p values <0,05 were considered to be significant (in bold); p values within ≥ 0,05 and <0,06 were considered borderline and were included in the following
multivariate regression model; p value was not calculated where a monotone likelihood was established.
Abbreviations: OC, oral cavity; OP, oropharynx.
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in tumour cells (p = 0.01; Table 3). As predictable, “senti-
nel lymphnodes” at diagnosis significantly influenced the
later appearance of more prominent lymphnodal lesions,
but this factor was not considered in the multivariate lo-
gistic regression model because of its unuttered prognostic
implication. Multivariate analysis corroborated that the
occurrence of precancerous lesions (HR, 3.773, p = 0.005),
and more incisively the presence of SDC2 in the stromal
compartment (HR, 7.652, p = 0.007), but not GPC6
expression or gender of the patient, were independent
prognostic markers for post-surgery secondary infiltra-
tions of lymphnodes (Table 4; Figure 5). If we then
accounted for both a history of precancerous lesions and
SDC2 stromal expression, the probability to develop post-surgical lymphnodal infiltration was significantly increased
(p = 0.001; Table 3; Figure 4).
Contrary to the above associations, univariate logistic
analyses revealed that the N classification , at time of surgi-
cal removal of the primary tumour mass, and up-regulated
transcription of SDC1 (Figure 4) were significantly associ-
ated with the formation of distant metastases ( p = 0.016 for
both correlations; Table 3). The frequency of GPC6 expres-
sion in neoplastic cells did not satisfy the limit of signifi-
cance (p = 0.052), but could be a potentially interesting
indicator to take into account in future investigations on
larger cohorts of patients. Conversely, multivariate analyses
reinforced the impact of N classification (HR, 4.38, p =
0.012) and down-regulated or unaltered SDC1 expression
(HR, 0.232, p = 0.013) as independent factors predicting the
Figure 4 (See legend on next page.)
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Figure 4 Differential PG expression correlates with clinical outcome. Survival and probability curves for the following correlations: (a) loco-regional
relapse vs de novo expression of NG2/CSPG4, (b) loco-regional relapse vs T group classification; (c) loco-regional relapse vs coincident NG2/CSPG4
expression and advanced T classification; (d) lymphnodal metastases vs enhanced SDC2 expression in stromal cells; (e) lymphnodal metastases
vs manifestation of precancerous lesions; (f) lymphnodal metastases vs the combination of both previous prognostic indicators; (g) distant
metastases vs up-regulated SDC1 expression; (h) distant metastases vs infiltration of cervical lymph nodes; (i) distant metastases vs the combination of
both previous prognostic indicators; (j) overall survival vs enhanced SDC2 expression in the stromal compartment; (k) overall survival vs N classification;
(l) overall survival vs the coincidence of both previously indicated events; (m) the occurrence of any of the clinical outcomes vs up-regulated SDC1
expression; (n) the occurrence of any of the clinical outcomes vs N classification; (o) the occurrence of any of the clinical outcomes vs the combination
of both above listed events; (p) overall survival, (q) distant metastases and (r) the occurrence of any of the clinical outcomes vs the combination of
SDC1 up-regulation, de novo expression of NG2/CSPG4 and stromal enhancement of SDC2 positivity. Abbreviations: LRFS, loco-regional relapse-free
survival; LMFS, lymphnodal metastasis-free survival; DMFS, distant metastasis-free survival; OS, overall survival, COsFS, clinical outcomes-free survival.
Farnedi et al. BMC Cancer  (2015) 15:352 Page 14 of 19formation of distant metastases, albeit with opposite trends,
(Table 4; Figure 5). When we next considered the combin-
ation of the unfavourable conditions represented by lymph-
nodal infiltration and up-regulation of SDC1 transcription,
we unfolded a significantly increased probability to develop
distant metastases (p = 0.004; Table 3; Figure 4). Note-
worthy was also the fact that 91% of patients with up-
regulated SDC1 transcription that developed distant
metastases within the follow-up period invariably suc-
cumbed the disease.
Advanced T classification (p = 0.038), T3-T4 grouping
(p = 0.043), positive N classification (p < 0.001; Figure 4),
up-regulation of SDC1 transcription (p = 0.036) and stro-
mal expression of SDC2 or GPC1 (p = 0.001 and p = 0.012
respectively; Table 3, Figure 4) were also found to be
strongly associated with disease-related death. Cervical
lymphnodal involvement (HR, 2.971, p = 0.005) and, more
markedly, synthesis of SDC2 in the stromal cells (HR,
8.671, p = 0.003), established two independent predictors
of survival (Table 4; Figure 5). The combination of these
two conditions further decreased the survival probability
of the patients (p < 0.001, Table 3; Figure 4).
In the evaluation of situations in which patients pre-
sented at any of the mentioned clinical outcomes, we
similarly found a tight correlation between advanced T
classification (p = 0.018), T3-T4 grouping (p = 0.005),
positive N classification (p < 0.001; Figure 4), up-regulation
of SDC1 mRNA (p = 0.013; Figure 4) and SDC2 stromal
reactivity (p = 0.002). Finally, in multivariate analyses, N
involvement (HR, 3.203, p < 0.001) and down-regulation or
unaltered SDC1 expression (HR, 0.429, p = 0.012), but not
T classification or SDC2 detection in stromal cells, were
independent factors with opposite trends for the prediction
of poor prognosis (Table 4; Figure 5). Even in this case the
combination of positive N classification and up-regulation
of SDC1 mRNA expression significantly increased the
probability of the patients to incur into a dismal disease
course (p < 0.001;Table 3; Figure 4).
We finally evaluated the disease course in patients
scoring positively for the 3 dismal prognostic indicators,
i.e. de novo expression of NG2/CSPG4, stromalabundance of SDC2 and up-regulation of SDC1 mRNA,
which, in an independent manner, associated with one
or more of the adverse clinical outcomes. This condi-
tions was found in 36 of the 173 patients (21%) and
within this patient subgroup 17% and 25%, respectively,
developed loco-regional secondary lesions or distant
metastases. Lymphnodal metastasis was observed in 11%
of the patients, whereas 33% of them succumbed to the
disease. Survival analyses revealed a strong association
between the PG pattern analyzed and the presence of
distant metastases (p < 0.002), disease-related deaths
(p = 0.004) and a cumulative bad prognosis (p < 0.004).
The Cox regression model ascertained that patients
not expressing simultaneously the three bad independ-
ent disease course markers resulted to have a best
prognosis in terms of putative development of distant
metastases (HR, 0.146, p = 0.002), for survival (HR,
0.272, p = 0.004) and for incurring into any of the un-
favourable clinical events under consideration (HR,
0.363, p = 0.003) (Table 4; Figure 5).Discussion
Despite the relatively high incidence of oral cavity
HNSCC, very few reliable prognostic and/or predictive
molecular markers are currently available for the routine
clinical management of the patients. In light of this defi-
ciency, we have explored the possibility that variation in
the expression of cell surface PGs, widely recognized to
be key factors in the control of tumour progression
[33,56-59], could afford more effective means of prog-
nosticating patients affected by these tumours. Indeed,
we find that, upon neoplastic transformation, epithelial
cells of the oral cavity and oropharynx modify their tran-
scriptional/translational rates of virtually all currently
known cell surface PGs. This led us to conclude that
transformation-dependent modulation of PG synthesis
may be part of the globally altered pattern of gene ex-
pression in these cells, as well as contribute to the can-
cer cell’s acquisition of a defined repertoire a cell surface
molecules capable of dictating their malignant behavior.
Table 4 Multivariate analyses of the prognostic implication of altered PG expression for the different clinical
outcomes1Estimated regression coefficient and confidence interval;
Prognostic indicator/PG Estimate1 (95% CI) SE2 p value3 HR4 Clinical outcome
T classification
T25 0.359 (0.153/0.565) 0.105 0,012 1.432 Loco-regional relapse
T3 1.857 (1.556/2.158) 0.153 6.404
T4 2.160 (1.956/2.364) 0.104 8.671
T3-T4 vs T1-T2 1.850 (1.691/2.009) 0.081 0.001 6.360 Loco-regional relapse
NG2/CSPG4 mRNA6
De novo expression vs
no expression
1.911 (1.735/2.087) 0.090 0.017 6.760 Loco-regional relapse
Precancerous lesions
Presence vs Absence 1.328 (1.184/1.471) 0.073 0.005 3.773 Lymphnodal metastases
SDC2 stroma
Positive vs Negative 2.035 (1.885/2.184) 0.076 0.007 7.652 Lymphnodal metastases
SDC2 stroma
Positive vs Negative 2.160 (2.022/2.298) 0.070 0.003 8.671 Disease-related deaths
N classification
Positive vs Negative 1.477 (1.326/1.628) 0.077 0.012 4.380 Distant metastasis
N classification
Positive vs Negative 1.089 (0.967/1.211) 0.062 0.005 2.971 Disease-related deaths
N classification
Positive vs Negative 1.164 (1.003/1.325) 0.082 <0.001 3.203 Any of the clinical outcomes7
SDC1 mRNA
↓ /= vs ↑ −1.460 (−1.612/-1.309) 0.077 0.013 0.232 Distant metastasis
SDC1 mRNA
↓ /= vs ↑ −0.845 (−1.007/-0.684) 0.082 0.012 0.429 Any of the clinical outcomes
SDC1 mRNA up-regulation +
NG2/CSPG4 mRNA de novo
expression + SDC2 stroma
Single condition vs combination of all 3 conditions8 −1.924 (−2.088/-1.760) 0.084 0.002 0.146 Distant metastasis
−1.302 (−1.459/-1.146) 0.080 0.004 0.272 Disease-related deaths
−1.014 (−1.194/-0.833) 0.092 0.003 0.363 Any of the clinical outcomes
1Estimated regression coefficient and confidence interval;
2Standard error of estimated regression coefficient;
3p value <0,05 were considered to be significant;
4Hazard Ratio estimated from Cox proportional hazard regression model;
5Compared to T1 stage;
6PG transcript expression (↓, down-regulated; ↑, up-regulated; =, not changed; De novo expression, de novo expressed in comparison to a healthy mucosal tissues
pool that was used as sample calibrator) could be grouped according to the trend of each PG gene in relation to the clinical outcomes;
7Is referred to a patient that had at least one of the other outcomes within the follow-up;
8Refers to the comparison between a situation in which all three indicated conditions were manifested (“combination of all 3 conditions”) versus either condition
alone or the combination of any two conditions;
Abbreviations: CI, Confidence Interval; HR, Hazard Ratio; SE, standard error.
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associated changes in their expressions in several types
of carcinomas, including those of thyroid, breast, colon,
skin, stomach and urogenital tract, and SDC1 is recog-
nized to be the best documented prognostic biomarker
[39,41,43,40,46,60-64]. Its expression pattern frequently
correlates with the differentiation status of the cells and
thereby with their malignancy degree [47,54,65-68]. Thischaracterizing trait of the SDC1 tumour-associated
expression was corroborated here, along with its wide-
spread distribution in neoplastic HNSCC lesions.
Although much less studied, SDC2 has also been re-
ported to be associated with malignant carcinoma lesions
in various anatomical sites/organs including head and
neck [63,69,70]. In this study, transcription/translation of
SDC2 was found to be more prominent in the
Figure 5 Cox proportional hazard analysis. Plot overview of Cox proportional hazard estimated regression coefficients of the resulting independent
prognostic factors for loco-regional recurrence, lymphnodal metastases, distant metastases, disease-related death and the occurrence of any of the
clinical outcomes.
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hence, the PG showed an expression pattern that was
complementary to SDC1. Notably, SDC2 was also ob-
served to be strongly enriched in neovascular struc-
tures, where it appeared to be associated with both
endothelial cells and pericytes. Our present mapping
study is the first to reveal a de novo expression of
SDC3 and SDC4 in oral cavity HNSCC and the accu-
mulation of SDC4 in areas of cell-cell contact
[22,24,25] within such lesions. Intracellular abundance
of SDCs in HNSCC cells may reflect the incapacity of
the cells to complete the post-translational processing
of these PGs and/or their transport and intercalation
into the cell membrane, or an accentuated internaliza-
tion and intracellular recycling process.
Several GPCs were also found to be misexpressed in
oral cavity HNSCC lesions, albeit with frequencies that
were generally lower than those seen for SDCs. GPC1,
known to be highly expressed in pancreatic and breast
carcinomas [32,33], was found to be the prevalent GPC of
these lesions, alongside with GPC3, which has independ-
ently been reported to be up-regulated in several other
tumour types and has a recognized value as prognosticfactor and putative therapeutic target in hepatocellular
carcinomas [34,35,37]. In this context, it is, however,
worth noting that GPC3 has also been proposed to act as
a potential tumour suppressor in certain neoplasia, show-
ing a putative transformation-dependent silencing of the
glypican [30,71-73].
When we applied univariate and multivariate meta-
analytical methods to correlate the observed PG expres-
sion patterns with clinically relevant disease outcomes
we unveiled striking associations. Appearance of NG2/
CSPG4, a PG with a precedent prognostic impact in
numerous solid tumours [74-82], was found to tightly
correlate with loco-regional tumour recurrence and,
hence, was disclosed to be the first ever to be described
molecular relapse predictor in oral cavity HNSCC. En-
hanced expression of GPC1 in the stromal compartment
of these lesions also closely correlated with tumour
recurrence and paralleled the more predictable prognostic
implication of tumour staging. Beside its prognostic role
in pancreatic cancer, there is currently no other indication
that altered expression of GPC1 may influence the course
of any tumour type. Another crucial finding of this study
was the close association betweenSDC2 up-regulation in
Farnedi et al. BMC Cancer  (2015) 15:352 Page 17 of 19the intralesional stromal compartment and the overall
survival of the patients carrying such SDC2-rich primary
lesions. Even in this case, the present study provides the
first evidence for such a prognostic relationship in any
cancer type and, similarly to the potential of NG2/CSPG4,
emphasizes that SDC2 may serve as a putative target
for prevention and/or treatment of relapsing oral cavity
HNSCC.
Conclusion
The present study provides the first evidence that altered
expression of cell surface-bound PGs is strongly links to
the formation and progression of oral cavity HNSCC.
Elective modulation of PG expression in primary oral
cavity HNSCC lesions correlates, in a predictive manner,
with several clinical outcomes and may therefore serve
as an adjunct in the molecular diagnosis of these tu-
mours. More specifically, enhanced expression of SDC2
in the tumour stroma significantly correlates with overall
survival and is indicative of lymphonodal metastasis,
whereas aberrant increased of SDC1 transcription is in-
dicative of the presence of distant metastases. Strikingly,
up-regulation of NG2/CSPG4 is tightly linked to loco-
regional recurrence of the tumour, underscoring the po-
tential of this biomarker to forcefully predict the clinical
course of oral cavity HNSCC patients.
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